SecBot SecBot
PRESS-RELEASE ·Filed Jul 14, 2026

CELC

Celcuity Inc.
BULLISH
Impact 8/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a transformative event for Celcuity, its first approved product with compelling Phase 3 data. Monitor commercial launch execution in late Q3 2026 and sNDA submission for the PIK3CA-mutated cohort. The VIKTORIA-2 first-line trial results will be the next major catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

REVTORPYK

◆ Mixed Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
Next catalyst
None dated

What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$91.51
T+0 close · Jul 14, 2026 · via day close
Latest settled
−25.83%
T+60 · $67.87
Vs SPY
−28.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $91.51entry
  2. T+1 · 4mo ago −3.52%α −2.98% · $88.29
  3. T+5 · 4mo ago −1.50%α −0.52% · $90.14
  4. T+20 · 3mo ago +0.62%α −1.72% · $92.08
  5. T+60 · 6w ago −25.83%α −28.37% · $67.87
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation, based on Phase 3 VIKTORIA-1 data showing a 76% reduction in risk of progression or death. This is the company's first approved product, transforming it from a clinical-stage biotech to a commercial-stage company, with launch expected in late Q3 2026.

Key Facts

  • FDA approved REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutation
  • First and only FDA-approved therapy inhibiting all class I PI3K isoforms and mTORC1/2
  • Phase 3 VIKTORIA-1: REVTORPYK triplet reduced risk of progression or death by 76% (HR=0.24) vs fulvestrant
  • Median PFS: 9.3 months (triplet) vs 2.0 months (fulvestrant); ORR 32% vs 1%
  • Commercial launch anticipated in late Q3 2026
  • sNDA for PIK3CA-mutated cohort to be submitted in Q3 2026
  • Ongoing Phase 3 VIKTORIA-2 trial in first-line advanced breast cancer

Financial Impact

First FDA approval transforms Celcuity from clinical-stage to commercial-stage; market cap $5.1B; no revenue or pricing disclosed

revenuemarket capcash runway

Risk Factors

  • Commercial execution risk for a first-time launch
  • Safety profile includes stomatitis (72%), rash, and hyperglycemia requiring monitoring
  • Competition from existing PI3K/AKT/mTOR inhibitors and CDK4/6 combinations
  • Dependence on single product for near-term revenue

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3327323

Track record

26 reports on CELC

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026